Neurology® Podcast

Dr. Stacey Clardy talks with Dr. Shelly Benjaminy about her paper on patients' perspectives from the chronic cerebrospinal venous insufficiency clinical trial in Canada.

Dr. Alex Menze interviews Dr. Kelly Gwathmey about her paper on a new quality of life measure for diabetic polyneuropathy.

The Delayed Recall episode for June takes a look at recent guidelines and developments in the field of multiple sclerosis treatment. In the first interview, Dr. Stacey Clardy and Dr. Alexander Rae-Grant discuss recent practice guidelines for multiple sclerosis, and talk about Dr. Rae-Grant's paper regarding these guidelines. This interview first aired on April 24, 2018. The second interview, from the May 15, 2018 episode, features Dr. Clardy speaking with Dr. Riley Bove about her recent paper on rituximab treatment during pregnancy. Next, hear Dr. Clardy speak with Dr. Raed Alroughani about relapse occurrence of MS during pregnancy, in an interview that appeared in the March 6, 2018 episode. In the conclusion to this month's episode, Dr. Mark Keegan and Dr. Gavin Giovannoni discuss the topic of alemtuzumab treatment for multiple sclerosis patients. This interview first appeared on April 18, 2017.

Dr. Roy Strowd talks with Dr. Saman Zafar about her paper on amateur fundus photography.

1. Featured Article: ABBY: A Phase 2 randomized trial of crenezumab in mild-to-moderate Alzheimer's Disease2. What's Trending: Epilepsy Birth Control Registry This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 22, 2018, print issue of Neurology. In the first segment, Dr. Jeff Burns talks with Dr. Jeffrey Cummings about results from the ABBY clinical trial on crenezumab as a potential treatment for mild to moderate Alzheimer Disease. For the "What's Trending" segment, Dr. Katherine Zarroli interviews Dr. Andrew Herzog about the Epilepsy Birth Control Registry (http://www.epilepsybirthcontrolregistry.org).

1. Featured Neurology® Clinical Practice Article: Ask a Neurologist: What Primary Care Providers ask, and reducing referrals through eConsults2. What's Trending: Update on arboviruses This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 15, 2018, print issue of Neurology. In the first segment, Dr. Heather Harle interviews Drs. Ana Bradi and Erin Keely about their paper on implementing an eConsult service between primary care providers and neurologists at the Ottawa Hospital. For the "What's Trending" segment, Dr. Amanda Piquet and Dr. Daniel Pastula discuss what every neurologist should know about mosquito- and tick-borne disease. DISCLOSURES: Dr. Harle and Dr. Bradi report no disclosures. Dr. Keely served as Associate Editor for Obstetric Medicine (2010 - 2017); and has received research support from CIHR (Partnerships for Health System Improvement, 367535 and 358003), Stemmler Medical Education Research Fund, and National Board of Medical Examiners, and Physicians' Services Incorporated Foundation. Dr. Piquet and Dr. Pastula report no disclosures.

1. Featured Article: Factors associated with treatment delays in pediatric refractory convulsive status epilepticus2. What's Trending: Focused ultrasound for treating tremorThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 8, 2018 issue of Neurology. In the first segment, Dr. Erika Axeen talks with Dr. Iván Fernández about his paper on factors that influence treatment delays in pediatric refractory convulsive status epilepticus. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jeff Elias on two recent articles published in the New England Journal of Medicine regarding focused ultrasound treatment for tremor. DISCLOSURES: Drs. Axeen and Crowell report no disclosures. Dr. Fernández has received research support from Epilepsy Research Fund, Fundación Alfonso Martín Escudero (Grant for the study of Epileptic Encephalopathies), and HHV6 Foundation. Dr. Elias reports grant support from InSightec, the BIRD Foundation, and the Focused Ultrasound Foundation.

This month's Delayed Recall episode includes interviews on topics that were highlighted in the Neurology Today "Best Advances of 2017" editorial. The episode starts with Dr. Andy Southerland's interview with Dr. Joseph Safdieh (April 10, 2018) that features a few editor's pick from the Best Advances in neurology in 2017. Following this clip, we have the full-length interview from the February 28, 2017 episode where Dr. Ted Burns speaks with Dr. Richard Finkel about nusinersen and spinal muscular atrophy. Next, in an interview from the February 13, 2018 podcast, Dr. Tesha Monteith focuses her interview with Dr. Peter Goadsby on CGRP treatments and migraine. In the third and final interview, Dr. Nicole Chiota-McCollum and Dr. Greg Albers regarding the DEFUSE trial results, which first aired in the April 17, 2018 episode of the podcast.

1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease2. What's Trending: Drug pricing This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the "What's Trending" segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Barrett has received research support from Axovant Sciences, Inc. (clinical trial site PI), Azevan Pharmaceuticals (clinical trial site PI), Merck Sharp & Dohme Corp. (Clinical trial site PI), Biogen (clinical trial site PI), Virginia Center of Alzheimer´s and Related Diseases Research Award Fund (PI), U.S. Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Career Progress Award (PI), and NIH (clinical trial site PI).Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Mr. Swetlitz is a reporter for StatNews.

1. Featured Article: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis2. What's Trending: Global, regional, and national burden of neurological disorders during 1990–2015 (from Lancet Neurology)This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 24, 2018, print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Alexander Rae-Grant about the AAN Practice Guideline on disease-modifying therapies for adults with multiple sclerosis. For the "What's Trending" segment, Dr. Jason Crowell interviews Dr. Theo Vos about findings from the Global Burden of Diseases, Injuries, and Risk Factors Study and the growing need for clinicians with neurologic expertise.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Rae-Grant has served on the Neurology Evidence Review Team, 2011-2018; receives publishing royalties from Handbook of Multiple Sclerosis (Springer Healthcare, 2010), Comprehensive review of clinical neurology, (Wolters Kluwer, 2012), 5 minute consult in neurology (Wolters Klower, 2012), Comprehensive review of clinical neurology second edition ( LWW, 2016), Ultimate review of neurology (DEMOS 2016), and Multiple Sclerosis and Related disorders (DEMOS, 2014); edits neurology chapters for Dynamic Medical, an online text book of medicine which is funded via library subscriptions; was involved in a clinical trial of biotin for multiple sclerosis with MedDay (no personal remuneration); and receives research support from NIH (grant #A6022304). Dr. Crowell reports no disclosures.